Journal Article

Hyperparasitemia and Blood Exchange Transfusion for Treatment of Children with Falciparum Malaria

Benjamin Mordmüller and Peter G. Kremsner

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 4, pages 850-852
Published in print April 1998 | ISSN: 1058-4838
Published online April 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/513926
Hyperparasitemia and Blood Exchange Transfusion for Treatment of Children with Falciparum Malaria

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

A substantial number of reports of cases and small investigations support blood exchange transfusion as a therapy for hyperparasitemia in cases of Plasmodium falciparum malaria, although a prospective and randomized study has never been undertaken. We report on 113 prospectively enrolled children in Lambaréné, Gabon, who had more than 10% parasitized erythrocytes and were treated with chemotherapy alone. All 86 patients with hyperparasitemia as the sole complication recovered uneventfully. Among the 27 patients who had additional complications, parasitemia levels as high as 81% responded well to chemotherapy alone. Two patients with cerebral malaria, who also had other complications and hence a poor prognosis, died. Hyperparasitemia itself might be important for the development of a fatal event in malaria, but a recommendation to perform a dangerous, expensive, and labor-intensive procedure such as blood exchange transfusion for its treatment should be based on substantial clinical research, especially in areas where malaria is a major health problem.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.